Dendrimer-based formulation of remdesivir

Posted by

Current formulations of remdesivir are required to be administered intravenously due to the drug’s low solubility, with each infusion taking up to two hours and requiring daily administration for either 5 or 10 days.

In contrast, Starpharma’s DEP® remdesivir is a highly water-soluble nanoparticle formulation of remdesivir with controlled release properties, which would potentially allow for less frequent dosing and use in a non-hospital setting, such as aged-care [1]. The solubility of DEP® remdesivir is 100‑fold higher than standard remdesivir. The benefit of DEP® remdesivir’s enhanced aqueous solubility is that it would enable subcutaneous injection rather than intravenous infusion, allowing for outpatient treatment and reducing the burden on hospitals.
  • DEP® remdesivir has been created to expand the potential application of remdesivir, by creating a long-acting version which could be administered subcutaneously rather than by intravenous infusion in hospital
  • DEP® remdesivir is a highly water-soluble nanoparticle formulation of the antiviral drug remdesivir (Veklury, Gilead) with improved pharmacokinetics
  • Gilead’s antiviral drug, remdesivir, is being utilised for the treatment of COVID-19



Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.